Morgan Stanley: Shandong Gold Mining (01787) Q3 results below expectations; maintain "Equal-weight" rating
The bank noted that Shandong Gold Mining had earlier lowered its 2026 production target from 49 tonnes to 36 to 38 tonnes, implying fourth-quarter production of approximately 10 to 12 tonnes; sales in the first nine months were 28.6 tonnes, drawing down 2.4 tonnes of inventory, and inventory drawdown is expected to continue in the fourth quarter.
Morgan Stanley released a research report stating that Shandong Gold Mining (01787)'s third-quarter results fell short of expectations, weakening the investment case for the stock; the bank maintains its "Equal-weight" rating and target price of HK$21.2.
The bank noted that the company's net profit for the first nine months of 2026 was RMB3.2 billion, down 19.6% year-on-year; the third quarter recorded a net loss of RMB363 million, compared with a profit of RMB2.1 billion in the second quarter and a profit of RMB1.1 billion in the third quarter of 2025. Third-quarter results were dragged down by lower sales volumes following a decline in output, a quarter-on-quarter decline in gross profit that was larger than that of the gold price and gold output, as well as a rise in the effective tax rate and an expansion in the allocation of minority interests.
The bank noted that the company had earlier lowered its 2026 production target from 49 tonnes to 36 to 38 tonnes, implying fourth-quarter output of approximately 10 to 12 tonnes. Sales in the first nine months were 28.6 tonnes, drawing down 2.4 tonnes of inventory, and inventory drawdown is expected to continue in the fourth quarter, providing some support to earnings.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process

Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares

CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process

Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares

CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%






